{"id":"active-compared-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vaccine candidate in Phase 3 development by Anhui Zhifei Longcom, it likely uses recombinant protein technology to present antigenic epitopes to the immune system, triggering both humoral and cellular immune responses. The exact target antigen and mechanism require confirmation from clinical trial data, as the specific indication is not provided.","oneSentence":"This is a recombinant protein vaccine designed to stimulate immune responses against a specific pathogen or disease target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:59:11.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07256912","phase":"PHASE4","title":"A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia","status":"NOT_YET_RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2026-04-01","conditions":"Vaccine Effectiveness, HPV Vaccination, Single Dose","enrollment":1266},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT05854381","phase":"PHASE1","title":"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-19","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT06569823","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over","status":"RECRUITING","sponsor":"Dynavax Technologies Corporation","startDate":"2024-06-17","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":764},{"nctId":"NCT07213089","phase":"PHASE2, PHASE3","title":"Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"BioNet-Asia Co., Ltd.","startDate":"2020-07-13","conditions":"Pertussis Whooping Cough","enrollment":290},{"nctId":"NCT05608005","phase":"PHASE1, PHASE2","title":"Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-03","conditions":"Influenza, Healthy Volunteers","enrollment":581},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT05506969","phase":"PHASE2","title":"Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-08-09","conditions":"Plague, Pneumonic, Plague, Vaccine-Preventable Diseases","enrollment":200},{"nctId":"NCT07055893","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies (Healthy Volunteers)","enrollment":390},{"nctId":"NCT07055880","phase":"PHASE2","title":"Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-07-28","conditions":"Rabies","enrollment":120},{"nctId":"NCT07055295","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies","enrollment":390},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT05815498","phase":"PHASE3","title":"A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-28","conditions":"COVID-19","enrollment":14246},{"nctId":"NCT06955728","phase":"PHASE4","title":"A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.","status":"NOT_YET_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2025-05-01","conditions":"RSV Infections, RSV Immunisation, Preterm Labour","enrollment":13000},{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT06608199","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","status":"RECRUITING","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2024-11-01","conditions":"Pneumococcal Vaccines, Pneumococcal Infections","enrollment":500},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT04351685","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2020-11-09","conditions":"Mycobacterium Tuberculosis Infection","enrollment":6940},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT04508309","phase":"PHASE3","title":"Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-15","conditions":"Cervical Cancer","enrollment":1025},{"nctId":"NCT06763783","phase":"PHASE4","title":"Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Region Skane","startDate":"2024-12-17","conditions":"Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis","enrollment":240},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06618196","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age","status":"NOT_YET_RECRUITING","sponsor":"LG Chem","startDate":"2024-10-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT06413121","phase":"PHASE3","title":"Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-05-06","conditions":"Diptheria Immunization, Tetanus Immunization, Pertussis Immunization","enrollment":1557},{"nctId":"NCT05249829","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-02-16","conditions":"SARS-CoV-2","enrollment":3548},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT00137696","phase":"NA","title":"Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2003-07","conditions":"Poliomyelitis","enrollment":473},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT04990466","phase":"PHASE2, PHASE3","title":"Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.","status":"WITHDRAWN","sponsor":"NeuroRx, Inc.","startDate":"2021-09-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT05433285","phase":"PHASE3","title":"Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-06-07","conditions":"COVID-19","enrollment":4050},{"nctId":"NCT05163561","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-01-09","conditions":"Poliomyelitis","enrollment":1072},{"nctId":"NCT05198596","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-30","conditions":"COVID-19 Vaccine","enrollment":250},{"nctId":"NCT05426343","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-09","conditions":"COVID-19 Vaccine","enrollment":200},{"nctId":"NCT04760236","phase":"PHASE3","title":"Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2021-10-06","conditions":"Cholera","enrollment":2530},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":"Rabies, Communicable Disease, Virus Diseases","enrollment":1000},{"nctId":"NCT05715918","phase":"PHASE3","title":"Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive\"","status":"UNKNOWN","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2022-04-01","conditions":"Vaccine","enrollment":300},{"nctId":"NCT03000998","phase":"NA","title":"Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake","status":"COMPLETED","sponsor":"Klein Buendel, Inc.","startDate":"2017-01-31","conditions":"Human Papillomavirus Virus, HPV","enrollment":432},{"nctId":"NCT05245838","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-01-10","conditions":"Shingles, Herpes Zoster, Vaccine-Preventable Diseases","enrollment":150},{"nctId":"NCT05293665","phase":"PHASE3","title":"Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine","status":"UNKNOWN","sponsor":"Vaxxinity, Inc.","startDate":"2022-03-16","conditions":"COVID-19 Vaccines","enrollment":944},{"nctId":"NCT05011526","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-10-08","conditions":"Covid19 Vaccine","enrollment":1030},{"nctId":"NCT05124340","phase":"PHASE2","title":"Safety and Tuberculin Conversion Following BCG Vaccination","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2021-12-01","conditions":"BCG Vaccination Reaction","enrollment":220},{"nctId":"NCT02274415","phase":"PHASE2","title":"Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-09-16","conditions":"Invasive Pneumococcal Infections, Sickle Cells Disease","enrollment":116},{"nctId":"NCT04525599","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator","status":"COMPLETED","sponsor":"Affinivax, Inc.","startDate":"2020-09-22","conditions":"Healthy Volunteers, Pneumococcal Disease","enrollment":75},{"nctId":"NCT04148118","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2020-01-08","conditions":"Anthrax","enrollment":84},{"nctId":"NCT05252936","phase":"NA","title":"Effectiveness of a Mayan Language Social Media Campaign on COVID-19 Vaccine Beliefs in Guatemala","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-03-14","conditions":"Vaccination Refusal","enrollment":5000},{"nctId":"NCT02654223","phase":"PHASE2","title":"Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy","status":"COMPLETED","sponsor":"Inmunotek S.L.","startDate":"2015-12-30","conditions":"Rhinitis, Rhinoconjunctivitis","enrollment":180},{"nctId":"NCT00427895","phase":"PHASE3","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02-27","conditions":"Pneumococcal Infections","enrollment":2141},{"nctId":"NCT04878796","phase":"","title":"Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)","status":"UNKNOWN","sponsor":"Azienda Socio Sanitaria Territoriale di Cremona","startDate":"2021-05-24","conditions":"Cancer, Covid-19, Vaccine Response","enrollment":300},{"nctId":"NCT03964012","phase":"PHASE3","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-08-20","conditions":"Meningococcal Meningitis","enrollment":1800},{"nctId":"NCT04765215","phase":"","title":"Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.","status":"UNKNOWN","sponsor":"Asoc. Prof. Erdoğan Selçuk Şeber","startDate":"2021-03-31","conditions":"Is the Coronovac Vaccine Effective in Patients Receiving Chemotherapy","enrollment":291},{"nctId":"NCT03703336","phase":"PHASE3","title":"Phase III Study of Liquid Formulation of ROTAVIN","status":"COMPLETED","sponsor":"Center for Research and Production of Vaccines and Biologicals, Vietnam","startDate":"2019-03-16","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":825},{"nctId":"NCT03518125","phase":"PHASE2","title":"BARDA Securing Anthrax Immunity For the Elderly","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2018-05-09","conditions":"Anthrax","enrollment":305},{"nctId":"NCT03111251","phase":"NA","title":"Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-03-01","conditions":"Human Papillomavirus (HPV)","enrollment":1000},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT02661854","phase":"PHASE2","title":"Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy","status":"UNKNOWN","sponsor":"Inmunotek S.L.","startDate":"2016-06-21","conditions":"Rhinitis, Rhinoconjunctivitis","enrollment":186},{"nctId":"NCT02390063","phase":"PHASE1","title":"Vaccination in Prostate Cancer (VANCE)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-06","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03169725","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-05-31","conditions":"Poliomyelitis","enrollment":1417},{"nctId":"NCT03208101","phase":"PHASE1","title":"A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-07-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT03467984","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2018-05-25","conditions":"Pneumococcal Infection","enrollment":230},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":"Healthy","enrollment":8374},{"nctId":"NCT01200368","phase":"PHASE3","title":"Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09-24","conditions":"Healthy Subjects","enrollment":551},{"nctId":"NCT02446743","phase":"PHASE3","title":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-17","conditions":"Infections, Meningococcal","enrollment":531},{"nctId":"NCT02859350","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-11","conditions":"Malaria","enrollment":135},{"nctId":"NCT02457689","phase":"PHASE1, PHASE2","title":"The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-07","conditions":"HIV","enrollment":30},{"nctId":"NCT02290509","phase":"PHASE3","title":"Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1350},{"nctId":"NCT02377843","phase":"NA","title":"Making Effective Human Papillomavirus (HPV) Vaccine Recommendations","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-03","conditions":"Human Papillomavirus","enrollment":30},{"nctId":"NCT01431196","phase":"PHASE2","title":"Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2011-02","conditions":"Stage II Breast Cancer, Stage III Breast Cancer","enrollment":29},{"nctId":"NCT00778258","phase":"PHASE2","title":"Study of Milk Allergy and Tolerance in Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-08","conditions":"Food Hypersensitivity, Milk Hypersensitivity","enrollment":170},{"nctId":"NCT01335412","phase":"","title":"Safety Surveillance After Immunization With IXIARO","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2011-03","conditions":"Japanese Encephalitis","enrollment":20000},{"nctId":"NCT01549119","phase":"PHASE1, PHASE2","title":"Phase I/IIa Dose-escalation Clinical Study of VAC-3S","status":"COMPLETED","sponsor":"InnaVirVax","startDate":"2012-02","conditions":"HIV-1 Infection","enrollment":33},{"nctId":"NCT01692886","phase":"PHASE3","title":"A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08","conditions":"Pneumococcal Infection","enrollment":1674},{"nctId":"NCT01896739","phase":"PHASE3","title":"A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-08","conditions":"Healthy Infants","enrollment":289},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240},{"nctId":"NCT00373958","phase":"PHASE3","title":"Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-09","conditions":"Vaccines, Pneumococcal","enrollment":666},{"nctId":"NCT01033877","phase":"PHASE3","title":"Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2010-01","conditions":"Healthy","enrollment":802},{"nctId":"NCT00366340","phase":"PHASE3","title":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Vaccines, Pneumococcal","enrollment":604},{"nctId":"NCT00311415","phase":"PHASE3","title":"Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-10","conditions":"Prevention of Meningococcal Infection","enrollment":257},{"nctId":"NCT00656097","phase":"PHASE2","title":"A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2008-03","conditions":"Rabies","enrollment":140},{"nctId":"NCT00546572","phase":"PHASE3","title":"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-11","conditions":"Pneumococcal Infections","enrollment":938},{"nctId":"NCT00170469","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed","status":"COMPLETED","sponsor":"PharmAthene UK Limited","startDate":"2005-03","conditions":"Bacillus Anthracis (Anthrax)","enrollment":226},{"nctId":"NCT00005002","phase":"PHASE3","title":"Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)","status":"UNKNOWN","sponsor":"Agouron Pharmaceuticals","startDate":"","conditions":"HIV Infections","enrollment":688}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15368,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active compared Vaccine","genericName":"Active compared Vaccine","companyName":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","companyId":"anhui-zhifei-longcom-biologic-pharmacy-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}